Sun Pharma to sell US arm Ohm Laboratories: Report

US market makes up half of Sun's revenue but business faces huge price erosion, regulatory issues

Sun Pharmaceutical Industries is looking to sell its US subsidiary, Ohm Laboratories, as it looks to consolidate its operations in its biggest overseas market, according to a television report.

The US market accounts for about half of the drug maker's consolidated revenue but the business is under pressure because of price erosion and regulatory issues.

Ohm Laboratories which has manufacturing facilities for oral solids in New Jersey became a part of Sun Pharma following its Ranbaxy acquisition in 2014. In 2015 Ohm Laboratories posted a revenue of Rs 2,063 crore and a net loss of Rs 118 crore.

Sun Pharma has a consolidated